Antipsychotics at doses >75 mg/day are associated with an increased risk for tardive dyskinesia (TD), according to a study ...

Significantly increased risk for tardive dyskinesia seen with doses >75 mg/day at last prescription and as maximum dose ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...

Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...

The prescription of high dose was associated with an increased risk of TD, and the highest risk was observed in the group receiving >300 mg/day. HealthDay News — Antipsychotics at doses >75 mg ...

Differentiating tardive dyskinesia from other movement disorders can be challenging. "One major criterion is the history of exposure to neuroleptic medications," said Jeff Bronstein, MD ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

Usually described as a splitting or multiple personality disorder, the concept of schizophrenia is not entirely but rather a ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

GOTHENBURG, SE / ACCESS Newswire / January 23, 2025 /IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, January ...

Teva Pharmaceutical Industries Ltd.'s (NYSE:TEVA) Huntington's disease and Tardive dyskinesia drug Austedo, Austedo XR. Abbvie Inc.'s (NYSE:ABBV) irritable bowel syndrome treatment Linzess and ...